Prime Medicine (PRME) FY2025 10-K Risk Factors: 11 New, 11 Dropped

What the changes say

Prime Medicine added 11 new risk disclosures covering financial instability, regulatory complexities for gene editing, data privacy, ESG, and social media.
The company updated risks on collaboration dependencies, macroeconomic factors, and patent protection standards.

What changed since the prior 10-K

New

NewRisks Related To Our Financial Position and Need for Additional Capital
temporarily reduced, we cannot predict the results of the U.S. government’s trade negotiations or the outcome of ongoing legal challenges to specific tariff policies
Trade negotiations, tariffs, and potential credit market instability could limit our liquidity and increase our borrowing costs.
NewRisks Related To Discovery, Development and Commercialization
impact of such changes, if any, may be. Based on these and other factors, health care providers and payors may decide that the benefits of these new therapies do not or will not outweigh their costs
Gene editing is new and the regulatory landscape is uncertain, which may cause health care providers and payors to conclude that costs outweigh benefits for our product candidates.
NewRisks Related To Discovery, Development and Commercialization
information or studies. There are equivalent processes and risks applicable to CTAs in other countries, including in Europe
Our personalized medicine approach may require complex umbrella or basket clinical trials spanning multiple mutations or diseases under a single IND.
NewRisks Related To Discovery, Development and Commercialization
evolving regulatory guidance governing gene and gene editing therapy products, the potential risk of improper modulation of a gene sequence and extended follow-up observation periods that may be required by regulatory agencies
Our Phase 1/2 trial results for PM359 may not predict later trial success, and our delivery technologies may cause serious adverse events or unexpected characteristics.
NewRisks Related To Discovery, Development and Commercialization
future product candidates uneconomical or obsolete, and we may not be successful in marketing any product candidates we may develop against competitors
Competitors could render our future product candidates uneconomical or obsolete if our patents expire or are successfully challenged.
NewRisks Related To Our Intellectual Property
technology similar or identical to ours and our ability to commercialize any product candidates we may develop may be adversely affected
Employees or third-party collaborators might breach confidentiality agreements and disclose patentable research before we file applications.
NewRisks Related To Our Intellectual Property
prosecution of patent applications and the enforcement or defense of our issued in-licensed patents and future issued patents
Supreme Court rulings like Myriad Genetics have narrowed patent protection for DNA molecules, increasing uncertainty over the validity of our in-licensed patents.
NewRisks Related To Regulatory and Other Legal Compliance Matters
costs and expenses in an effort to comply with them, and may be required to modify or restrict our data collection and use practices
State breach notification laws and FTC enforcement of privacy policies create complex compliance obligations regarding our data collection practices.
NewRisks Related To Ownership of Our Common Stock
outside of our control. Even if this is not the case, our actions may subsequently be determined to be insufficient by various stakeholders, and we may be subject to investor or regulator engagement on our ESG efforts, even if such initiatives are currently voluntary
Unfavorable ESG ratings from institutional investors using third-party benchmarks could negatively impact our share price and cost of capital.
NewRisks Related To Ownership of Our Common Stock
others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management
Our charter provisions and Delaware law include anti-takeover defenses like a classified board and blank check preferred stock that discourage change-in-control transactions.
NewRisks Related To Ownership of Our Common Stock
The increasing use of social media platforms presents risks and challenges
Internal and external employee use of social media to discuss our product candidates creates regulatory noncompliance and enforcement risks.

Dropped

DroppedRisks Related To Our Financial Position and Need for Additional Capital
A severe or prolonged economic downturn or additional global financial crises could result in a variety of risks to our business, including weakened demand for any product candidates we develop or our ability to raise additional capital when needed on acceptable terms, if at all
DroppedRisks Related To Discovery, Development and Commercialization
Therapeutics, see “Business—Our License and Collaboration Agreements—Strategic relationship with Beam Therapeutics.”
DroppedRisks Related To Discovery, Development and Commercialization
for many of the product candidates we may develop are small, we must be able to successfully identify patients and achieve market acceptance in the medical community in order to secure a significant market share to maintain profitability and growth
DroppedRisks Related To Our Relationships with Third Parties
business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators, which further increases competition we face in seeking potential collaborations
DroppedRisks Related To Our Intellectual Property
disruptions to our business relationships with our licensors, we could lose license rights that are important to our business
DroppedRisks Related To Our Intellectual Property
intellectual property rights, we would need to enter into license agreements with such institutions, and such license agreements may not be available on commercially reasonable terms or at all
DroppedRisks Related To Our Intellectual Property
and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace
DroppedRisks Related To Our Intellectual Property
finds that our patent specifications do not enable such broad classes of gene editors, a court could find such claims invalid
DroppedRisks Related To Regulatory and Other Legal Compliance Matters
additional regulations or restrictions on the development and commercialization of any product candidates we may develop, which may be difficult to predict
Severe economic downturns or U.S. government debt ceiling and budget deficit concerns could weaken demand or capital raising.
DroppedRisks Related To Ownership of Our Common Stock
result, the information we provide stockholders will be different than the information that is available with respect to certain other public companies
DroppedRisks Related To Ownership of Our Common Stock
If we fail to maintain effective internal control over financial reporting in the future, we may not be able to accurately report our financial condition or results of operations which may adversely affect investor confidence in us and, as a result, the value of our common stock

Reworded

93% rewrittenRisks Related To Discovery, Development and Commercialization
Similarly, other gene editing or gene therapy approaches may be determined to be more attractive than Prime Editing. Moreover, if we decide to develop gene editing technologies other than those involving Prime Editing, we cannot be certain we will be able to obtain rights to such technologies
Updated to refine comparisons against other gene editing approaches and potential difficulties in acquiring rights to alternative technologies.
87% rewrittenRisks Related To Our Relationships with Third Parties
If conflicts arise between us and our collaborators or strategic partners, these parties may act in a manner adverse to us and could limit our ability to implement our strategies or we could lose license rights that are important to our business
Added specific references to license and collaboration agreements with Beam and Broad Institute regarding technology and product candidates.
Was: If conflicts arise between us and our collaborators or strategic partners, these parties may act in a manner adverse to us and could limit our ability to implement our strategies
84% rewrittenRisks Related To Our Intellectual Property
Changes in patent law in the United States and in non-U.S. jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our Prime Editing platform technology and product candidates
Trimmed text regarding U.S. Congress patentability standards while retaining core risks associated with changing patent laws.
82% rewrittenRisks Related To Our Financial Position and Need for Additional Capital
Unfavorable macroeconomic conditions or market volatility resulting from geopolitical developments or national or global economic conditions, including those affecting the financial services industry, could adversely affect our business, financial condition or results of operations
Expanded macroeconomic risks to explicitly include disruptions or changes within U.S. governmental agencies and federal shutdowns.
79% rewrittenRisks Related To Ownership of Our Common Stock
If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed
Clarified that failure to implement required new or improved financial controls could cause reporting obligation failures under SOX Section 404.
76% rewrittenRisks Related To Ownership of Our Common Stock
Increased attention to, and evolving expectations for, environmental, climate change, social, and governance, or ESG, initiatives could increase our costs, harm our reputation, or otherwise adversely impact our business
Updated ESG risk language to note potential factors outside our control affecting the completion of voluntary sustainability initiatives.
74% rewrittenRisks Related To Regulatory and Other Legal Compliance Matters
Reductions in government operations may also delay necessary manufacturing facility inspections by regulators and adversely affect the supply of any product candidates we may develop
Added specific mention of SEC disruptions, staffing reductions, and updated the FDA funding expiration date to September 30, 2026.
69% rewrittenRisks Related To Ownership of Our Common Stock
We are an “emerging growth company” and a “smaller reporting company,” and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors
Maintained emerging growth company disclosures regarding reduced reporting requirements under the JOBS Act and SOX Section 404.
66% rewrittenRisks Related To Ownership of Our Common Stock
Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition
62% rewrittenRisks Related To Regulatory and Other Legal Compliance Matters
We are subject to stringent laws, rules, regulations, policies, standards and contractual obligations related to data privacy and security and changes in such laws, rules, regulations, policies, standards and contractual obligations could adversely affect our business
60% rewrittenRisks Related To Employee Matters, Managing Growth and Information Technology
Our future success depends on our ability to retain our key employees and to attract, retain and motivate qualified personnel
59% rewrittenRisks Related To Employee Matters, Managing Growth and Information Technology
Artificial intelligence presents risks and challenges that can impact our business including by posing security risks to our confidential information, proprietary information, and personal data
55% rewrittenRisks Related To Ownership of Our Common Stock
The U.S. Congress, the Trump administration, or any new administration may make substantial changes to fiscal, tax, and other federal policies that may adversely affect our business
52% rewrittenRisks Related To Regulatory and Other Legal Compliance Matters
We may seek rare pediatric disease designation for certain of our current or future product candidates, but we might not receive such designation, and even if we do, we may not be able to realize the intended benefits of such designation
46% rewrittenRisks Related To Regulatory and Other Legal Compliance Matters
Healthcare and other reform legislation may increase the difficulty and cost for us and any collaborators we may have to obtain marketing approval of and commercialize any product candidates we may develop and affect the prices we, or they, may obtain
38% rewrittenRisks Related To Discovery, Development and Commercialization
Adverse public perception of genetic therapies and of gene editing and Prime Editing in particular, may negatively impact regulatory approval of, and/or demand for, our potential products
38% rewrittenRisks Related To Our Relationships with Third Parties
If we are not able to establish collaborations on a timely basis, on commercially reasonable terms, or at all, we may have to alter, reduce or delay our development and commercialization plans or increase our expenditures to fund development or commercialization activities at our own expense
27% rewrittenRisks Related To Discovery, Development and Commercialization
Social media campaigns and demand for expanded access to our current and future product candidates could negatively affect our reputation and harm our business
27% rewrittenRisks Related To Our Financial Position and Need for Additional Capital
We have incurred significant losses since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability
25% rewrittenRisks Related To Our Relationships with Third Parties
Any therapies that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us
23% rewrittenRisks Related To Ownership of Our Common Stock
We face risks related to health epidemics, pandemics and other widespread outbreaks of contagious disease, which could significantly disrupt our operations, impact our financial results or otherwise adversely impact our business
21% rewrittenRisks Related To Our Intellectual Property
Third parties may assert that our employees, consultants, or advisors have wrongfully used or disclosed confidential information or misappropriated trade secrets

All 73 risk factors

Headings as the filing states them, in filing order.

Risks Related To Our Financial Position and Need for Additional Capital

01We have incurred significant losses since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability27% rewritten
02Because our existing cash, cash equivalents, and investments will not be sufficient to fund our operations, as currently planned, for more than one year beyond the filing date of this Annual Report on Form 10-K, we have determined that there is substantial doubt regarding our ability to continue as a going concern
03We will need substantial additional funding. If we are unable to raise capital when needed, we will be forced to delay, reduce, eliminate or prioritize among our research and product development programs or future commercialization efforts
04Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates we may develop
05Our short operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability
06We have never generated revenue from product sales and may never become profitable
07Our future ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited
08Unfavorable macroeconomic conditions or market volatility resulting from geopolitical developments or national or global economic conditions, including those affecting the financial services industry, could adversely affect our business, financial condition or results of operations82% rewritten
09temporarily reduced, we cannot predict the results of the U.S. government’s trade negotiations or the outcome of ongoing legal challenges to specific tariff policiesNew

Risks Related To Discovery, Development and Commercialization

10Similarly, other gene editing or gene therapy approaches may be determined to be more attractive than Prime Editing. Moreover, if we decide to develop gene editing technologies other than those involving Prime Editing, we cannot be certain we will be able to obtain rights to such technologies93% rewritten
11impact of such changes, if any, may be. Based on these and other factors, health care providers and payors may decide that the benefits of these new therapies do not or will not outweigh their costsNew
12information or studies. There are equivalent processes and risks applicable to CTAs in other countries, including in EuropeNew
13If we do not successfully commercialize any product candidates we may develop, we could experience a material harm to our business
14evolving regulatory guidance governing gene and gene editing therapy products, the potential risk of improper modulation of a gene sequence and extended follow-up observation periods that may be required by regulatory agenciesNew
15We may also consider additional delivery modes, which may carry additional known and unknown risks
16future product candidates uneconomical or obsolete, and we may not be successful in marketing any product candidates we may develop against competitorsNew
17Adverse public perception of genetic therapies and of gene editing and Prime Editing in particular, may negatively impact regulatory approval of, and/or demand for, our potential products38% rewritten
18Clinical trial and product liability lawsuits against us could divert our resources and could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop
19If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
20We also may encounter problems hiring and retaining the experienced scientific, quality control and manufacturing personnel needed to manage our manufacturing process, which could result in delays in our production or difficulties in maintaining compliance with applicable regulatory requirements
21Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates
22Social media campaigns and demand for expanded access to our current and future product candidates could negatively affect our reputation and harm our business27% rewritten

Risks Related To Our Relationships with Third Parties

23If conflicts arise between us and our collaborators or strategic partners, these parties may act in a manner adverse to us and could limit our ability to implement our strategies or we could lose license rights that are important to our business87% rewritten
24We expect to rely on third parties to conduct our clinical trials and some aspects of our research, as well as some aspects of our delivery methods, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing
25Any therapies that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us25% rewritten
26If we are not able to establish collaborations on a timely basis, on commercially reasonable terms, or at all, we may have to alter, reduce or delay our development and commercialization plans or increase our expenditures to fund development or commercialization activities at our own expense38% rewritten

Risks Related To Our Intellectual Property

27technology similar or identical to ours and our ability to commercialize any product candidates we may develop may be adversely affectedNew
28Our in-licensed issued patents and owned and in-licensed patent applications may not provide sufficient protection of our Prime Editing technologies and our future product candidates or result in any competitive advantage
29We have limited foreign intellectual property rights and may not be able to protect our intellectual property and proprietary rights throughout the world
30We may not be successful in acquiring or in-licensing necessary rights to key technologies or any product candidates we may develop
31We may become involved in lawsuits to protect or enforce our future patents, or the issued patents or future patents of our licensors, which could be expensive, time consuming and unsuccessful and could result in a finding that such patents are unenforceable or invalid
32Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
33Changes in patent law in the United States and in non-U.S. jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our Prime Editing platform technology and product candidates84% rewritten
34prosecution of patent applications and the enforcement or defense of our issued in-licensed patents and future issued patentsNew
35Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
36If we do not obtain PTE for any product candidates we may develop, our business may be materially harmed
37If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
38Third parties may assert that our employees, consultants, or advisors have wrongfully used or disclosed confidential information or misappropriated trade secrets21% rewritten
39If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
40Intellectual property rights do not necessarily address all potential threats

Risks Related To Regulatory and Other Legal Compliance Matters

41Reductions in government operations may also delay necessary manufacturing facility inspections by regulators and adversely affect the supply of any product candidates we may develop74% rewritten
42If we fail to comply with healthcare laws, we could face substantial penalties and our business, operations and financial conditions could be adversely affected
43Healthcare and other reform legislation may increase the difficulty and cost for us and any collaborators we may have to obtain marketing approval of and commercialize any product candidates we may develop and affect the prices we, or they, may obtain46% rewritten
44The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates could limit our product revenues
45We may seek rare pediatric disease designation for certain of our current or future product candidates, but we might not receive such designation, and even if we do, we may not be able to realize the intended benefits of such designation52% rewritten
46We may seek designation for our Prime Editing platform technology as a designated platform technology, but we might not receive such designation, and even if we do, such designation may not lead to a faster regulatory review or approval process
47Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading
48Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain product candidates outside of the United States and require us to develop and implement costly compliance programs
49We are subject to stringent laws, rules, regulations, policies, standards and contractual obligations related to data privacy and security and changes in such laws, rules, regulations, policies, standards and contractual obligations could adversely affect our business62% rewritten
50costs and expenses in an effort to comply with them, and may be required to modify or restrict our data collection and use practicesNew
51Existing regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates

Risks Related To Employee Matters, Managing Growth and Information Technology

52Our future success depends on our ability to retain our key employees and to attract, retain and motivate qualified personnel60% rewritten
53We expect to expand our research, development, delivery, manufacturing, commercialization, regulatory and future sales and marketing capabilities over time, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations
54Artificial intelligence presents risks and challenges that can impact our business including by posing security risks to our confidential information, proprietary information, and personal data59% rewritten

Risks Related To Ownership of Our Common Stock

55We do not know whether a market will be sustained for our common stock or what the market price of our common stock will be, and, as a result, it may be difficult for you to sell your shares of our common stock
56The market price of our common stock may be volatile, which could result in substantial losses for investors
57If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline
58Future sales or issuances of our common stock in the public market, or the perception of such sales, could cause our stock price to fall
59Insiders have substantial influence over us, which could limit your ability to affect the outcome of key transactions, including a change of control
60We are an “emerging growth company” and a “smaller reporting company,” and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors69% rewritten
61We have incurred, and continue to incur, increased costs as a result of operating as a public company, and our management must devote substantial time to compliance initiatives and corporate governance practices
62We do not expect to pay any dividends for the foreseeable future. Investors may never obtain a return on their investment
63Increased attention to, and evolving expectations for, environmental, climate change, social, and governance, or ESG, initiatives could increase our costs, harm our reputation, or otherwise adversely impact our business76% rewritten
64outside of our control. Even if this is not the case, our actions may subsequently be determined to be insufficient by various stakeholders, and we may be subject to investor or regulator engagement on our ESG efforts, even if such initiatives are currently voluntaryNew
65Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition66% rewritten
66If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed79% rewritten
67others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current managementNew
68These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock
69Our second amended and restated bylaws designate specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit stockholders’ ability to obtain a favorable judicial forum for disputes with us
70We face risks related to health epidemics, pandemics and other widespread outbreaks of contagious disease, which could significantly disrupt our operations, impact our financial results or otherwise adversely impact our business23% rewritten
71Our operations are vulnerable to interruption by disasters, terrorist activity, business disruptions and other events beyond our control, which could harm our business
72The U.S. Congress, the Trump administration, or any new administration may make substantial changes to fiscal, tax, and other federal policies that may adversely affect our business55% rewritten
73The increasing use of social media platforms presents risks and challengesNew

Other Prime Medicine 10-Ks

FY2024 10-K risk factors
73 risks
Prime Medicine faces substantial going concern doubt with an accumulated deficit of $687.2 million as of December 31, 2024. The company relies entirely on third-party licenses like Broad Institute and Beam Therapeutics without owning issued patents. Operations depend heavily on unproven Prime Editing technology and early-stage rare disease pipelines.
Filed Feb 28, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.